CBIO:NSD-Catalyst Biosciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.20

Change

+0.25 (+4.20)%

Market Cap

USD 0.13B

Volume

0.23M

Average Target Price

USD 18.00 (+190.32%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Its products include Marzeptacog alfa (activated), a subcutaneously administered next-generation engineered coagulation Factor VIIa that has completed Phase II development for individuals with hemophilia A or B with inhibitors; and Dalcinonacog alfa, a next-generation engineered coagulation Factor IX therapy that has completed Phase IIb clinical trials for the treatment of hemophilia B. The company also develops CB 2679d-GT, an early stage Factor IX gene therapy construct for Hemophilia B; CB 2782-PEG, a long acting anti-C3 protease for the treatment of dry age-related macular degeneration (AMD); and SQ systemic complement inhibitors pipeline. The company has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other serious inflammatory retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+1.04 (+0.46%)

USD58.95B 22.22 17.39
REGN Regeneron Pharmaceuticals, Inc

+1.98 (+0.39%)

USD54.85B 18.84 14.53
MRNA Moderna, Inc

+25.71 (+20.24%)

USD50.27B N/A N/A
SGEN Seagen Inc

+1.19 (+0.70%)

USD30.27B 63.87 62.62
ALXN Alexion Pharmaceuticals, Inc

-1.72 (-1.39%)

USD27.10B 28.74 26.92
BNTX BioNTech SE

+14.25 (+12.96%)

USD26.48B -99,999.99 N/A
RPRX Royalty Pharma plc

+1.00 (+2.40%)

USD26.01B 22.60 9.74
GMAB Genmab A/S

+1.48 (+3.99%)

USD24.32B 26.59 2.61
BGNE BeiGene, Ltd

-30.20 (-10.56%)

USD24.20B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CBIO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.96% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.96% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 12.32% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.32% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -85.34% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.34% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 15.63% N/A N/A 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.63% N/A N/A 72% C-
Risk Return Profile  
Volatility (Standard Deviation) 144.62% N/A N/A 6% F
Risk Adjusted Return 10.81% N/A N/A 40% F
Market Capitalization 0.13B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.30 N/A N/A N/A N/A
Price/Book Ratio 1.36 N/A N/A N/A N/A
Price / Cash Flow Ratio -3.01 N/A N/A N/A N/A
EV/EBITDA 0.28 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -58.11% N/A N/A N/A N/A
Return on Invested Capital -60.84% N/A N/A N/A N/A
Return on Assets -31.75% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.62 N/A N/A N/A N/A
Short Percent 4.45% N/A N/A N/A N/A
Beta 2.12 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.